BGIM
ALXN

Brandywine Global Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Brandywine Global Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-128,267
Closed -$23.6M – 747
2021
Q2 		$23.6M Sell
128,267
-176,462
-58% -$30.3M 0.17% 147
2021
Q1 		$46.6M Sell
304,729
-76,856
-20% -$11.9M 0.35% 71
2020
Q4 		$59.6M Buy
381,585
+10,445
+3% +$1.34M 0.5% 46
2020
Q3 		$42.5M Sell
371,140
-3,966
-1% -$428K 0.42% 62
2020
Q2 		$42.1M Buy
375,106
+182,569
+95% +$19.4M 0.43% 54
2020
Q1 		$17.3M Buy
+192,537
New +$18.9M 0.21% 109

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Brandywine Global Investment Management's ALXN Position: Q3 2021 in Review

Brandywine Global Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 128,267 shares — an estimated $23.6M sold.

Brandywine Global Investment Management first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $59.6M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Brandywine Global Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Brandywine Global Investment Management sold 128,267 Alexion Pharmaceuticals shares in Q3 2021, an estimated $23.6M.
  • Brandywine Global Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Brandywine Global Investment Management's Alexion Pharmaceuticals position peaked at $59.6M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Brandywine Global Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.